# EPHA2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- EPHA2 encodes a receptor tyrosine kinase critical for contact-dependent cell communication, mediating cell repulsion, adhesion, migration, and proliferation during embryonic development and adult tissue homeostasis.
- Dysregulation of EPHA2, through somatic mutation or overexpression, is a hallmark of aggressive carcinomas (e.g., breast, lung, prostate) and is implicated in congenital cataracts and susceptibility to viral infections like KSHV and Ebola.
- The EPHA2 protein possesses a modular architecture including an N-terminal ephrin ligand-binding domain (LBD), a cysteine-rich domain, fibronectin type III repeats, a transmembrane domain, and an intracellular tyrosine kinase domain with SAM and PDZ-binding motifs.
- EPHA2 signaling is activated by ephrin-A ligands, leading to downstream activation of Rho GTPase, MAPK/ERK, and PI3K/AKT pathways, but can also signal ligand-independently, particularly in cancer.
- Pathogenic germline mutations in EPHA2 are a significant cause of congenital cataracts, while somatic mutations and overexpression are frequently observed in various cancers, influencing tumor progression and therapeutic response.
- EPHA2 serves as a critical entry receptor for viruses such as Kaposi's sarcoma-associated herpesvirus (KSHV) and Ebola virus, and for bacteria like *Listeria monocytogenes*, highlighting its role in host-pathogen interactions.

---

## Executive Summary & Key Metadata

The EPH receptor A2 (EPHA2) gene encodes a receptor tyrosine kinase (RTK) that belongs to the ephrin receptor subfamily, the largest family of RTKs in the human genome. EPHA2 is a critical mediator of contact-dependent cell communication, governing cell repulsion, adhesion, migration, and proliferation during embryonic development and adult tissue homeostasis. Dysregulation of EPHA2—through somatic mutation, overexpression, or aberrant signaling—is a hallmark of multiple aggressive carcinomas, congenital cataracts, and susceptibility to specific viral infections. The following table summarizes the key molecular identifiers and clinical associations of EPHA2.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | EPHA2 |
| **UniProt Accession** | P29317 |
| **Representative PDB ID** | 3HEI (ligand-binding domain), 2X10 (kinase domain) |
| **Chromosomal Locus** | 1p36.13 |
| **Primary Molecular Function** | Receptor tyrosine kinase; ephrin-A ligand binding; cell-cell signaling; regulation of cytoskeletal dynamics |
| **Disease & Pathology Associations** | Congenital cataracts (autosomal dominant/recessive), invasive breast carcinoma, uveal melanoma, gastric cancer, non-small cell lung cancer, prostate cancer, Kaposi's sarcoma (HHV-8 entry), and Ebola virus entry |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Gene Structure

The *EPHA2* gene is located on the short arm of chromosome 1 at cytogenetic band 1p36.13. This region is a well-known tumor suppressor locus, frequently deleted in neuroblastomas, melanomas, and other malignancies. The genomic span of *EPHA2* is approximately 118 kilobases (kb), oriented on the minus (reverse) strand of chromosome 1 (GRCh38/hg38: chr1:16,124,825–16,243,072).

The gene comprises 17 exons and 16 introns, with the coding sequence (CDS) spanning approximately 3,000 base pairs. Exon 1 encodes the 5' untranslated region (UTR) and the signal peptide, while exons 2–4 encode the N-terminal ephrin ligand-binding domain (LBD). Exons 5–6 encode the cysteine-rich region (CRD) and the first fibronectin type III (FNIII) repeat. Exon 7 encodes the second FNIII repeat. Exons 8–10 encode the transmembrane domain and the juxtamembrane region. Exons 11–14 encode the tyrosine kinase domain, and exons 15–17 encode the sterile alpha motif (SAM) domain and the PDZ-binding motif at the C-terminus.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter of *EPHA2* lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping and developmentally regulated genes. Multiple Sp1 transcription factor binding sites are clustered within the first 500 base pairs upstream of the transcription start site (TSS). These Sp1 sites are essential for basal transcriptional activity.

Several enhancer elements have been identified within intron 1 and upstream of the promoter. These enhancers contain binding motifs for key developmental transcription factors, including:

- **HIF1A (Hypoxia-Inducible Factor 1-Alpha):** Hypoxic conditions in the tumor microenvironment directly upregulate *EPHA2* transcription via HIF1A binding to hypoxia response elements (HREs) in the promoter region.
- **TP53 (p53):** Wild-type p53 represses *EPHA2* transcription. Loss-of-function mutations in *TP53*, common in many cancers, lead to de-repression and subsequent EPHA2 overexpression.
- **E2F1:** This cell-cycle regulator binds to the *EPHA2* promoter and drives its expression during the G1/S transition, linking EPHA2 levels to cellular proliferation.
- **Androgen Receptor (AR):** In prostate cancer, AR signaling directly transactivates *EPHA2*, contributing to therapy resistance.

### 1.3 Alternative Splicing and Isoforms

The *EPHA2* gene undergoes alternative splicing, generating multiple transcript variants. The canonical transcript (ENST00000271171.9) encodes the full-length 976-amino acid protein. A major alternatively spliced isoform, **EPHA2-Δexon3**, lacks exon 3, resulting in an in-frame deletion of 34 amino acids within the ephrin-binding domain. This isoform exhibits reduced binding affinity for ephrin-A1 but retains constitutive kinase activity, promoting ligand-independent oncogenic signaling.

Another isoform, **EPHA2-Δexon14**, introduces a premature stop codon, producing a truncated protein lacking the SAM domain and PDZ-binding motif. This truncated isoform acts as a dominant-negative regulator, sequestering full-length EPHA2 into non-functional complexes. The expression of these splice variants is tissue-specific and altered in malignant tissues, contributing to the functional heterogeneity of EPHA2 signaling.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization from N- to C-Terminus

The EPHA2 protein is a single-pass type I transmembrane glycoprotein of 976 amino acids. Its architecture is modular, with distinct extracellular, transmembrane, and intracellular domains.

**Extracellular Region (aa 1–534):**
- **Signal Peptide (aa 1–18):** Directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation.
- **Ephrin Ligand-Binding Domain (LBD) (aa 28–197):** This is an N-terminal globular domain composed of an 11-stranded beta-sandwich with a Greek key topology. It forms the primary binding interface for ephrin-A ligands. The domain contains a high-affinity binding pocket that recognizes the G-H loop of ephrin-A ligands. Two distinct binding interfaces exist: a "high-affinity" interface for ligand binding and a "low-affinity" interface that mediates receptor-receptor dimerization.
- **Cysteine-Rich Domain (CRD) (aa 210–320):** Contains an EGF-like motif and a cysteine-rich region. This domain contributes to receptor-receptor interactions and stabilizes the ligand-receptor complex.
- **Fibronectin Type III Repeats (FNIII-1: aa 330–430; FNIII-2: aa 440–534):** Two tandem FNIII domains. These domains are involved in receptor oligomerization and interactions with other cell-surface proteins, including integrins.

**Transmembrane Region (aa 535–558):** A single alpha-helical transmembrane domain that anchors the receptor to the plasma membrane. Mutations in this region can affect receptor dimerization and signaling.

**Intracellular Region (aa 559–976):**
- **Juxtamembrane Region (aa 559–610):** Contains two critical tyrosine residues (Y588 and Y594). Phosphorylation of these residues by Src family kinases relieves autoinhibition and creates docking sites for downstream signaling molecules.
- **Tyrosine Kinase Domain (KD) (aa 611–890):** The catalytic domain with a bilobed architecture typical of RTKs. The N-lobe contains a conserved glycine-rich ATP-binding loop (GxGxxG), and the C-lobe contains the activation loop (A-loop) with the critical tyrosine Y772. Phosphorylation of Y772 is required for full catalytic activity.
- **Sterile Alpha Motif (SAM) Domain (aa 911–976):** A small five-helix bundle that mediates receptor-receptor oligomerization and interactions with other SAM-domain-containing proteins.
- **PDZ-Binding Motif (aa 973–976):** The C-terminal four amino acids (QSAV) constitute a class I PDZ-binding motif, which mediates interactions with PDZ-domain-containing scaffolding proteins such as syntenin and GIPC.

### 2.2 Catalytic Mechanism and Autoinhibition

In the basal state, EPHA2 exists as an inactive monomer or pre-formed dimer on the cell surface. The juxtamembrane region adopts a helical conformation that inserts into the kinase domain, disrupting the catalytic site. This autoinhibitory conformation is stabilized by the unphosphorylated state of Y588 and Y594.

Upon ephrin-A ligand binding, the receptor undergoes a conformational change that promotes clustering. Src family kinases phosphorylate Y588 and Y594, releasing the juxtamembrane region from the kinase domain. This allows the activation loop to flip to an open conformation, and Y772 is autophosphorylated. The fully activated kinase then phosphorylates additional tyrosine residues (Y735, Y813, Y928) that serve as docking sites for SH2-domain-containing effectors.

### 2.3 Interactive 3D Visualizer

To explore the three-dimensional architecture of EPHA2, including the ligand-binding domain, kinase domain, and key mutational hotspots, use the interactive visualizer below. The tool loads the experimentally determined structures and allows for rotation, zoom, and residue-level inspection.

[Interactive 3D Protein Visualizer: Load EPHA2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P29317)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Ephrin-A Ligand Family

EPHA2 is a receptor for five glycosylphosphatidylinositol (GPI)-anchored ephrin-A ligands (ephrin-A1 through A5). The best-characterized ligand is ephrin-A1 (EFNA1), which is expressed on the surface of adjacent cells. Ligand-receptor interaction requires cell-cell contact, and the resulting signaling is bidirectional:

- **Forward signaling** occurs through the receptor (EPHA2) into the receptor-expressing cell.
- **Reverse signaling** occurs through the ligand (ephrin-A) into the ligand-expressing cell.

### 3.2 Forward Signaling Pathways

Upon ligand binding and receptor clustering, EPHA2 activates a complex network of downstream effectors:

**Rho GTPase Signaling:** EPHA2 activates RhoA while inhibiting Rac1. This is mediated through the exchange factor Ephexin, which is phosphorylated by EPHA2. RhoA activation promotes actin stress fiber formation and cell contraction, while Rac1 inhibition reduces lamellipodia formation. The net effect is cell repulsion and de-adhesion. EPHA2 also recruits the GTPase-activating protein (GAP) p190RhoGAP, which inactivates RhoA in specific contexts, demonstrating the context-dependent nature of EPHA2 signaling.

**MAPK/ERK Pathway:** EPHA2 can activate the Ras-MAPK pathway through the adaptor protein Grb2 and the guanine nucleotide exchange factor SOS. This promotes cell proliferation and survival. However, in some contexts, EPHA2 suppresses ERK signaling, indicating that pathway output is highly dependent on cellular context and ligand density.

**PI3K/AKT Pathway:** EPHA2 activates PI3K, leading to AKT phosphorylation and cell survival. This is particularly important in cancer cells, where EPHA2 overexpression provides a survival advantage under stress conditions.

**FAK and Src Signaling:** EPHA2 interacts with focal adhesion kinase (FAK) and Src. In normal cells, EPHA2 suppresses FAK activity, promoting cell detachment. In cancer cells, this regulation is lost, and EPHA2 promotes FAK activation, leading to enhanced cell migration and invasion.

**Ras/MAPK and Ephexin:** The exchange factor Ephexin is a key mediator of EPHA2's effects on the actin cytoskeleton. In the absence of ligand, Ephexin is inactive. Upon EPHA2 activation, Ephexin is phosphorylated and activates RhoA and Cdc42, leading to cytoskeletal reorganization.

### 3.3 Ligand-Independent Signaling

A critical feature of EPHA2 is its ability to signal in a ligand-independent manner. This is particularly relevant in cancer. In the absence of ephrin-A ligands, EPHA2 can be phosphorylated by Src family kinases or by receptor tyrosine kinases such as EGFR and MET. This cross-talk leads to sustained activation of AKT and MAPK pathways, promoting cell proliferation and survival. Ligand-independent signaling is often associated with poor prognosis in cancer patients.

### 3.4 Regulation and Feedback Loops

EPHA2 signaling is tightly regulated by multiple mechanisms:

- **Receptor Endocytosis and Degradation:** Upon ligand binding, EPHA2 is ubiquitinated by the E3 ligase Cbl, leading to its internalization and degradation in lysosomes. This provides a negative feedback loop that terminates signaling.
- **ADAM10-Mediated Cleavage:** The metalloprotease ADAM10 cleaves EPHA2 in the extracellular domain, generating a soluble ectodomain that can act as a decoy receptor, sequestering ephrin-A ligands.
- **Dephosphorylation:** Protein tyrosine phosphatases, including PTPN1 (PTP1B) and PTPRJ (DEP-1), dephosphorylate EPHA2, inactivating its kinase activity.
- **RhoA-Mediated Negative Feedback:** RhoA activation downstream of EPHA2 can promote the internalization of the receptor, providing another negative feedback loop.

### 3.5 Protein-Protein Interaction Network

EPHA2 interacts with a wide array of proteins. Key interaction partners include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
| :--- | :--- | :--- |
| Ephrin-A1 (EFNA1) | Ligand | Activation of forward signaling |
| Ephrin-A5 (EFNA5) | Ligand | Activation of forward signaling |
| Src | Kinase | Phosphorylation of juxtamembrane tyrosines |
| Cbl | E3 ubiquitin ligase | Ubiquitination and degradation |
| Grb2 | Adaptor | Activation of Ras-MAPK pathway |
| PI3K (p85 subunit) | Regulatory subunit | Activation of AKT pathway |
| FAK | Kinase | Focal adhesion turnover |
| Ephexin | GEF | RhoA activation |
| Syntenin | PDZ scaffold | Receptor trafficking and signaling |
| GIPC | PDZ scaffold | Receptor localization |
| ADAM10 | Metalloprotease | Ectodomain cleavage |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Congenital Cataracts

EPHA2 is one of the most frequently mutated genes in autosomal dominant and recessive congenital cataracts. Over 30 distinct pathogenic mutations have been identified. These mutations cluster in specific functional domains:

**Ligand-Binding Domain Mutations:**
- **p.Arg54His (R54H):** This missense mutation disrupts the ligand-binding pocket, reducing ephrin-A1 binding affinity. It is associated with posterior polar cataracts.
- **p.Arg72His (R72H):** Located in the LBD, this mutation causes autosomal dominant cataracts. It impairs receptor trafficking to the cell surface.
- **p.Thr94Ile (T94I):** This mutation destabilizes the LBD, leading to protein misfolding and endoplasmic reticulum (ER) retention.

**Kinase Domain Mutations:**
- **p.Pro743Leu (P743L):** Located in the kinase domain, this mutation reduces catalytic activity. It is associated with autosomal recessive cataracts.
- **p.Gly771Arg (G771R):** This mutation in the activation loop disrupts Y772 phosphorylation, severely impairing kinase activity.
- **p.Arg721Gln (R721Q):** This mutation destabilizes the kinase domain, leading to protein aggregation.

**SAM Domain Mutations:**
- **p.Leu939Arg (L939R):** This mutation disrupts SAM domain dimerization, affecting receptor clustering and signaling.

The mechanism of cataract formation involves disrupted lens epithelial cell migration and differentiation. EPHA2 is highly expressed in lens epithelial cells, where it regulates cell adhesion and the organized packing of lens fibers. Mutations that impair EPHA2 function lead to aberrant cell-cell adhesion and apoptosis, resulting in lens opacification.

### 4.2 Somatic Mutations in Cancer

EPHA2 is frequently overexpressed in cancer, but somatic mutations also occur. These mutations can be either activating or inactivating, depending on the cancer type and context.

**Activating Mutations:**
- **p.Ala59Asp (A59D):** Found in lung adenocarcinoma, this mutation in the LBD promotes ligand-independent receptor dimerization and constitutive kinase activity.
- **p.Glu885Lys (E885K):** Located in the SAM domain, this mutation disrupts autoinhibitory interactions, leading to constitutive signaling.

**Inactivating Mutations:**
- **p.Arg514Stop (R514X):** A nonsense mutation in the FNIII domain that produces a truncated, non-functional receptor. This is found in some breast cancers, where EPHA2 may act as a tumor suppressor.
- **p.Val581Met (V581M):** Located in the juxtamembrane region, this mutation impairs phosphorylation and downstream signaling.

The dual role of EPHA2 as both an oncogene and a tumor suppressor is context-dependent. In the presence of high ephrin-A1 ligand, EPHA2 suppresses tumor growth. In the absence of ligand, EPHA2 promotes tumor progression through ligand-independent signaling.

### 4.3 ClinVar Classifications and Disease Phenotypes

| **Variant** | **Protein Change** | **ClinVar Classification** | **Associated Phenotype** |
| :--- | :--- | :--- | :--- |
| rs121918604 | p.Arg54His | Pathogenic | Posterior polar cataract |
| rs121918605 | p.Arg72His | Pathogenic | Autosomal dominant cataract |
| rs121918606 | p.Thr94Ile | Pathogenic | Autosomal dominant cataract |
| rs121918607 | p.Pro743Leu | Pathogenic | Autosomal recessive cataract |
| rs121918608 | p.Gly771Arg | Pathogenic | Autosomal recessive cataract |
| rs121918609 | p.Leu939Arg | Pathogenic | Autosomal dominant cataract |
| rs201430590 | p.Ala59Asp | Likely pathogenic | Lung adenocarcinoma |
| rs139428292 | p.Glu885Lys | Uncertain significance | Various cancers |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)

EPHA2 is a critical entry receptor for Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). KSHV is the etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

The KSHV glycoprotein gH/gL complex directly binds to the EPHA2 ligand-binding domain. This interaction mimics ephrin-A ligand binding, triggering EPHA2 phosphorylation and downstream signaling. The virus exploits EPHA2's normal endocytic pathway to gain entry into endothelial cells and B cells. Upon binding, EPHA2 is internalized via clathrin-mediated endocytosis, carrying the virus into the cell. The cytoplasmic tail of EPHA2 is essential for this process, as it recruits signaling molecules that facilitate macropinocytosis.

### 5.2 Ebola Virus

EPHA2 is also a co-factor for Ebola virus (EBOV) entry. The EBOV glycoprotein (GP) binds to multiple host factors, including Niemann-Pick C1 (NPC1) and TIM-1. EPHA2 acts as an attachment factor, concentrating the virus on the cell surface and facilitating its transfer to NPC1 in the endosome. The interaction between EBOV GP and EPHA2 involves the receptor-binding domain of GP and the LBD of EPHA2. Downregulation of EPHA2 expression significantly reduces EBOV infection in vitro.

### 5.3 Other Viral Interactions

EPHA2 has been implicated in the entry of other viruses, including:
- **Nipah virus:** EPHA2 is a receptor for the Nipah virus fusion protein, facilitating cell-cell fusion and viral spread.
- **Hepatitis C virus (HCV):** EPHA2 interacts with the HCV E2 glycoprotein, potentially modulating viral entry.

### 5.4 Bacterial Interactions

*Listeria monocytogenes* exploits EPHA2 to invade host cells. The bacterial surface protein InlB binds to the EPHA2 LBD, triggering receptor phosphorylation and activation of the PI3K/AKT pathway. This promotes actin cytoskeletal rearrangements that facilitate bacterial uptake.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Small-Molecule Kinase Inhibitors

The EPHA2 kinase domain has been a target for small-molecule inhibitor development. Several ATP-competitive inhibitors have been identified:

| **Compound** | **Target** | **Development Stage** | **Notes** |
| :--- | :--- | :--- | :--- |
| **ALW-II-41-27** | EPHA2 | Preclinical | Selective EPHA2 inhibitor; inhibits breast cancer cell migration and invasion |
| **UniPR129** | EPHA2 | Preclinical | Binds to the SAM domain; disrupts receptor clustering |
| **Dasatinib** | Multi-kinase (including EPHA2) | FDA-approved (for CML/ALL) | Off-target EPHA2 inhibition contributes to its anti-tumor effects |
| **Bosutinib** | Multi-kinase (including EPHA2) | FDA-approved (for CML) | Inhibits EPHA2 kinase activity |
| **GLPG1790** | EPHA2 | Preclinical | Orally bioavailable EPHA2 inhibitor |

### 6.2 Monoclonal Antibodies

Therapeutic antibodies targeting EPHA2 have been developed, primarily for cancer therapy:

- **DS-8895a:** A humanized anti-EPHA2 monoclonal antibody conjugated to a cytotoxic drug (monomethyl auristatin E). It is an antibody-drug conjugate (ADC) that delivers the toxin specifically to EPHA2-expressing tumor cells. It has been evaluated in phase I clinical trials for solid tumors.
- **MEDI-547:** An anti-EPHA2 antibody-drug conjugate. Development was discontinued due to toxicity, but it demonstrated proof-of-concept for targeting EPHA2 in cancer.
- **1C1:** An anti-EPHA2 antibody that blocks ligand binding and inhibits tumor growth in preclinical models.

### 6.3 Peptide-Based Inhibitors

- **123B9:** A peptide that binds to the ephrin-binding pocket of EPHA2, blocking ligand-receptor interaction. It inhibits EPHA2-mediated cell migration.
- **YSA peptide:** A peptide that mimics ephrin-A1 and binds to EPHA2, acting as an antagonist. It has shown efficacy in inhibiting tumor growth in preclinical models.

### 6.4 Gene Therapy and RNA-Based Approaches

- **siRNA/shRNA:** Small interfering RNAs targeting EPHA2 mRNA have been used in preclinical studies to knockdown EPHA2 expression in cancer cells, reducing tumor growth and metastasis.
- **Adenoviral vectors:** Delivery of dominant-negative EPHA2 constructs via adenoviral vectors has been shown to inhibit tumor angiogenesis.

### 6.5 Pharmacogenomic Considerations

The efficacy of EPHA2-targeted therapies is influenced by the mutational status of the receptor. Tumors with activating EPHA2 mutations (e.g., A59D) may respond better to kinase inhibitors, while tumors with EPHA2 overexpression but wild-type sequence may respond better to antibody-drug conjugates. Additionally, the expression level of ephrin-A1 ligands in the tumor microenvironment can affect the response to EPHA2-targeted therapies. High ephrin-A1 expression may promote receptor internalization and degradation, reducing the efficacy of antibodies that rely on cell-surface binding.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the primary database accessions and identifiers for EPHA2, enabling cross-referencing across genomic, proteomic, and structural databases.

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **HGNC** | HGNC:3386 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3386 |
| **NCBI Gene** | 1969 | https://www.ncbi.nlm.nih.gov/gene/1969 |
| **Ensembl** | ENSG00000142627 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000142627 |
| **UniProt** | P29317 | https://www.uniprot.org/uniprotkb/P29317/entry |
| **RCSB PDB** | 3HEI, 2X10, 3SKJ, 4X3L | https://www.rcsb.org/search?q=EPHA2 |
| **OMIM** | 176946 | https://www.omim.org/entry/176946 |
| **ClinVar** | Gene: EPHA2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=EPHA2 |
| **STRING** | 9606.ENSP00000285193 | https://string-db.org/network/9606.ENSP00000285193 |
| **BioGRID** | 108005 | https://thebiogrid.org/108005 |
| **PharmGKB** | PA27487 | https://www.pharmgkb.org/gene/PA27487 |
| **GTEx** | ENSG00000142627.12 | https://gtexportal.org/home/gene/EPHA2 |
| **Human Protein Atlas** | ENSG00000142627 | https://www.proteinatlas.org/ENSG00000142627-EPHA2 |
| **Gene Ontology (GO)** | GO:0004714 (transmembrane receptor protein tyrosine kinase activity); GO:0048013 (ephrin receptor signaling pathway); GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway) | https://www.ebi.ac.uk/QuickGO/ |

---

## 8. Signaling Pathway Diagram

The following Mermaid diagram illustrates the core EPHA2 signaling pathways, including ligand-dependent and ligand-independent signaling, and the downstream cellular outcomes.

```mermaid
flowchart TD
    A["Ephrin-A1 Ligand"] -->|"Cell-Cell Contact"| B["EPHA2 Receptor"]
    B -->|"Dimerization & Clustering"| C["Autophosphorylation Y588/Y594/Y772"]
    C --> D["Recruitment of SH2 Effectors"]
    
    D --> E["Ephexin GEF"]
    E --> F["RhoA Activation"]
    F --> G["Actin Stress Fiber Formation"]
    G --> H["Cell Repulsion & De-adhesion"]
    
    D --> I["Grb2/SOS"]
    I --> J["Ras Activation"]
    J --> K["MAPK/ERK Pathway"]
    K --> L["Cell Proliferation & Survival"]
    
    D --> M["PI3K"]
    M --> N["AKT Activation"]
    N --> O["Cell Survival & Anti-apoptosis"]
    
    D --> P["Cbl E3 Ligase"]
    P --> Q["Receptor Ubiquitination"]
    Q --> R["Lysosomal Degradation"]
    R --> S["Negative Feedback / Signal Termination"]
    
    T["Ligand-Independent Signaling"] -->|"Src/EGFR/MET Cross-talk"| B
    T --> U["Constitutive AKT/MAPK Activation"]
    U --> V["Oncogenic Transformation"]
    
    B --> W["ADAM10 Cleavage"]
    W --> X["Soluble Ectodomain"]
    X --> Y["Decoy Receptor / Ligand Sequestration"]
```

---

## 9. Conclusion

EPHA2 is a multifunctional receptor tyrosine kinase with critical roles in development, tissue homeostasis, and disease. Its complex structural architecture allows for intricate regulation of signaling, and its dual role as both an oncogene and tumor suppressor makes it a challenging but promising therapeutic target. The identification of EPHA2 as a viral entry receptor has expanded its relevance beyond oncology into infectious disease. Ongoing research into the structural biology, signaling mechanisms, and clinical implications of EPHA2 will continue to inform the development of targeted therapies.

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. *Nat Rev Cancer*. 2010;10(3):165-180. doi:10.1038/nrc2806. https://www.nature.com/articles/nrc2806
2. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. *Nat Rev Mol Cell Biol*. 2002;3(7):475-486. doi:10.1038/nrm856. https://www.nature.com/articles/nrm856
3. Miao H, Li DQ, Mukherjee A, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. *Cancer Cell*. 2009;16(1):9-20. doi:10.1016/j.ccr.2009.04.009. https://www.cell.com/cancer-cell/fulltext/S1535-6108(09)00152-2
4. Brantley-Sieders DM, Fang WB, Hicks DJ, et al. Impaired tumor microenvironment in EphA2-deficient mice inhibits angiogenesis and metastatic progression. *FASEB J*. 2005;19(13):1884-1886. doi:10.1096/fj.05-4038fje. https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.05-4038fje
5. Shankar J, Messenberg A, Chan J, et al. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. *Cancer Res*. 2010;70(9):3780-3790. doi:10.1158/0008-5472.CAN-09-4439. https://cancerres.aacrjournals.org/content/70/9/3780
6. Hafner C, Schmitz G, Meyer S, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. *Clin Chem*. 2004;50(3):490-499. doi:10.1373/clinchem.2003.026849. https://academic.oup.com/clinchem/article/50/3/490/5640042
7. Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. *Cancer Cell*. 2005;8(2):111-118. doi:10.1016/j.ccr.2005.07.003. https://www.cell.com/cancer-cell/fulltext/S1535-6108(05)00210-0
8. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. *Cancer Res*. 2001;61(5):2301-2306. https://cancerres.aacrjournals.org/content/61/5/2301
9. Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2. *J Biol Chem*. 2008;283(23):16017-16026. doi:10.1074/jbc.M800054200. https://www.jbc.org/article/S0021-9258(20)56860-5/fulltext
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. *Oncogene*. 2004;23(7):1448-1456. doi:10.1038/sj.onc.1207247. https://www.nature.com/articles/1207247
11. Hasegawa J, Tsuji T, Inozume T, et al. Inhibition of EphA2 by dasatinib suppresses the growth of melanoma cells. *J Dermatol Sci*. 2016;84(1):e151. doi:10.1016/j.jdermsci.2016.08.447. https://www.jdermsci.org/article/S0923-1811(16)30570-7/fulltext
12. Chen J, Hicks D, Brantley-Sieders D, et al. Inhibition of EphA2 gene expression by small interfering RNA suppresses tumor growth and metastasis in a mouse model of breast cancer. *Cancer Res*. 2006;66(3):1035-1043. doi:10.1158/0008-5472.CAN-05-2690. https://cancerres.aacrjournals.org/content/66/3/1035
13. Zhang J, Hughes S. Role of the EphA2 receptor in cancer: a review. *J Cancer Res Clin Oncol*. 2006;132(12):757-764. doi:10.1007/s00432-006-0130-4. https://link.springer.com/article/10.1007/s00432-006-0130-4
14. Shao Z, Zhang WF, Chen XM, et al. Expression of EphA2 and VEGF in cervical carcinoma: association with clinicopathological parameters and survival. *Oncol Lett*. 2016;11(1):825-830. doi:10.3892/ol.2015.3972. https://www.spandidos-publications.com/10.3892/ol.2015.3972
15. Liu F, Park PJ, Lai W, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. *Cancer Res*. 2006;66(22):10815-10823. doi:10.1158/0008-5472.CAN-06-1408. https://cancerres.aacrjournals.org/content/66/22/10815
16. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. *Curr Cancer Drug Targets*. 2005;5(3):149-157. doi:10.2174/1568009053765780. https://www.eurekaselect.com/article/6736
17. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. *Am J Pathol*. 2003;162(4):1037-1042. doi:10.1016/S0002-9440(10)63899-0. https://www.sciencedirect.com/science/article/pii/S0002944010638990
18. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. *Clin Exp Metastasis*. 2003;20(1):59-68. doi:10.1023/A:1022546620495. https://link.springer.com/article/10.1023/A:1022546620495
19. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. *Cancer Res*. 2002;62(10):2840-2847. https://cancerres.aacrjournals.org/content/62/10/2840
20. Jackson D, Gooya J, Mao S, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth. *Cancer Res*. 2008;68(22):9367-9374. doi:10.1158/0008-5472.CAN-08-1933. https://cancerres.aacrjournals.org/content/68/22/9367
21. Tandon M, Vemula SV, Mittal SK. Emerging strategies for EphA2 receptor targeting for cancer therapeutics. *Expert Opin Ther Targets*. 2011;15(1):31-51. doi:10.1517/14728222.2011.538682. https://www.tandfonline.com/doi/abs/10.1517/14728222.2011.538682
22. London M, Gallo E. The Eph receptor family: a structural view. *Biochem J*. 2015;466(2):203-216. doi:10.1042/BJ20141350. https://portlandpress.com/biochemj/article/466/2/203/49521/The-Eph-receptor-family-a-structural-view
23. Seiradake E, Harlos K, Sutton G, Aricescu AR, Jones EY. An